Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Entrada Therapeutics (TRDA) Assets Average (2022 - 2025)

Entrada Therapeutics (TRDA) has 4 years of Assets Average data on record, last reported at $395.1 million in Q4 2025.

  • For Q4 2025, Assets Average fell 26.89% year-over-year to $395.1 million; the TTM value through Dec 2025 reached $395.1 million, down 26.89%, while the annual FY2025 figure was $451.8 million, 9.22% down from the prior year.
  • Assets Average reached $395.1 million in Q4 2025 per TRDA's latest filing, down from $430.8 million in the prior quarter.
  • Across five years, Assets Average topped out at $568.3 million in Q3 2024 and bottomed at $263.3 million in Q4 2022.
  • Average Assets Average over 4 years is $441.0 million, with a median of $477.1 million recorded in 2023.
  • Peak YoY movement for Assets Average: soared 81.23% in 2023, then decreased 26.89% in 2025.
  • A 4-year view of Assets Average shows it stood at $263.3 million in 2022, then soared by 81.23% to $477.1 million in 2023, then rose by 13.28% to $540.5 million in 2024, then fell by 26.89% to $395.1 million in 2025.
  • Per Business Quant database, its latest 3 readings for Assets Average were $395.1 million in Q4 2025, $430.8 million in Q3 2025, and $467.6 million in Q2 2025.